Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Avidity Biosciences Announced New Long-term AOC 1001 Data From The Marina-OLE Trial Showing Reversal Of Disease Progression In Myotonic Dystrophy Type 1 Patients Across Multiple Endpoints

Author: Benzinga Newsdesk | March 04, 2024 08:28am

These endpoints are the same key endpoints that will be used in the global Phase 3 HARBOR trial for people living with DM1.vidity is accelerating the global Phase 3 HARBOR trial initiation to the second quarter of 2024.

Posted In: RNA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist